P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton et al., Global burden of hypertension: analysis of worldwide data, The Lancet, vol.365, issue.9455, pp.217-223, 2005.
DOI : 10.1016/S0140-6736(05)70151-3

H. Godet-thobie, Niveau tensionnel moyen et prévalence de l'hypertension artérielle chez les adultes de 18 à 74 ans, Étude Nationale Nutrition Santé, 2006.

D. Calhoun, D. Jones, S. Textor, D. Goff, T. Murphy et al., Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension, vol.51, issue.6, pp.1403-1422, 2008.
DOI : 10.1161/HYPERTENSIONAHA.108.189141

B. Egan, Y. Zhao, R. Axon, W. Brzezinski, and F. Kc, Uncontrolled and Apparent Treatment Resistant Hypertension in the United States Circulation, NHANES survey, 1988.

L. , D. Evans, J. Larson, M. , O. Donnell et al., Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community, Hypertension, vol.36, pp.594-599, 2000.

L. , D. Evans, J. Larson, M. Levy, and D. , Treatment and control of hypertension in the community: a prospective analysis, Hypertension, vol.40, pp.640-646, 2002.

D. Agostino and R. , General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study, Circulation, vol.117, issue.6, p.743, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.699579

A. The, C. Officers, . For, . Allhat-collaborative-research, and . Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, vol.288, pp.2981-2997, 2002.

F. He and G. Macgregor, Effect of longer-term modest salt reduction on blood pressure

M. Weinberger, S. Cohen, J. Miller, F. Luft, C. Grim et al., Dietary Sodium Restriction as Adjunctive Treatment of Hypertension, JAMA: The Journal of the American Medical Association, vol.259, issue.17, pp.2561-2565, 1988.
DOI : 10.1001/jama.1988.03720170037030

P. Anyfanti, E. Gavriilaki, and S. Douma, Evaluating the True Prevalence of Resistant Hypertension, Hypertension, vol.58, issue.4, 2011.
DOI : 10.1161/HYPERTENSIONAHA.111.178111

E. Bis, K. K. Pimenta, S. Gaddam, and . Oparil, Effects ofdietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial, Hypertension, vol.54, issue.3, pp.475-481, 2009.

T. Vollmer, W. Sacks, F. Ard, J. Appel, L. Bray et al., Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial, Annals of Internal Medicine, vol.135, issue.12, pp.1019-1028, 2001.
DOI : 10.7326/0003-4819-135-12-200112180-00005

R. Wildman, D. Gu, P. Muntner, G. Huang, J. Chen et al., Alcohol intake and hypertension subtypes in Chinese men, Journal of Hypertension, vol.23, issue.4, pp.737-743, 2005.
DOI : 10.1097/01.hjh.0000163141.82212.5f

M. Aguilera, A. Sierra, A. Coca, R. Estruch, J. Fernández-solá et al., Effect of Alcohol Abstinence on Blood Pressure : Assessment by 24-Hour Ambulatory Blood Pressure Monitoring, Hypertension, vol.33, issue.2, pp.653-657, 1999.
DOI : 10.1161/01.HYP.33.2.653

S. Whelton, A. Chin, X. Xin, and J. He, Effect of Aerobic Exercise on Blood Pressure, Annals of Internal Medicine, vol.136, issue.7, pp.493-503, 2002.
DOI : 10.7326/0003-4819-136-7-200204020-00006

M. A. Weber, Treatment of Patients with Hypertension and Arthritis Pain: New Concepts, The American Journal of Medicine, vol.122, issue.5, pp.16-22, 2009.
DOI : 10.1016/j.amjmed.2009.03.004

G. C. Curhan, W. C. Willett, B. J. Rosner, and . Stampfer, Frequency of Analgesic Use and Risk of Hypertension in Younger Women, Archives of Internal Medicine, vol.162, issue.19, pp.2204-2208, 2002.
DOI : 10.1001/archinte.162.19.2204

. Curhan, Nonnarcotic analgesic use and the risk of hypertension in US women, Hypertension, vol.40, issue.5, pp.604-608, 2002.

A. G. Johnson, T. V. Nguyen, and R. O. Day, Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis, Annals of Internal Medicine, vol.121, issue.4, pp.289-300, 1994.
DOI : 10.7326/0003-4819-121-4-199408150-00011

A. Johnson, T. Nguyen, and R. Day, Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis, Annals of Internal Medicine, vol.121, issue.4, pp.289-300, 1994.
DOI : 10.7326/0003-4819-121-4-199408150-00011

K. Radack, C. Deck, and S. Bloomfield, Ibuprofen Interferes with the Efficacy of Antihypertensive Drugs, Annals of Internal Medicine, vol.107, issue.5, pp.628-635, 1987.
DOI : 10.7326/0003-4819-107-5-628

P. Conlin, T. Moore, S. Swartz, E. Barr, L. Gazdick et al., Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients, Hypertension, vol.36, issue.3, pp.461-465, 2000.
DOI : 10.1161/01.HYP.36.3.461

G. A. Cinotti and F. Pugliese, Prostaglandins in blood pressure regulation, Kidney International, vol.34, issue.25, pp.57-60, 1988.

G. A. Fitzgerald, COX-2 and beyond: approaches to prostaglandin inhibition in human disease, Nature Reviews Drug Discovery, vol.5, issue.11, pp.879-890, 2003.
DOI : 10.1038/384644a0

A. Whelton, G. Schulman, and C. Wallemark, Effects of Celecoxib and Naproxen on Renal Function in the Elderly, Archives of Internal Medicine, vol.160, issue.10, pp.1465-1470, 2000.
DOI : 10.1001/archinte.160.10.1465

T. J. Schnitzer, A. J. Kivitz, R. S. Lipetz, N. Sanders, and A. Hee, Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee, Arthritis & Rheumatism, vol.90, issue.6, pp.827-837, 2005.
DOI : 10.1002/art.21586

C. N. Baerwald, P. Verdecchia, B. Duquesroix, H. Frayssinet, and T. Ferreira, Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: A randomized, double-blind, parallel-group, multicenter study, Arthritis & Rheumatism, vol.25, issue.12, pp.3635-3644, 2010.
DOI : 10.1002/art.27694

C. P. Cannon, S. P. Curtis, and G. A. Fitzgerald, Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison, Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use, pp.1771-1781, 1996.
DOI : 10.1016/S0140-6736(06)69666-9

D. A. Sica, Angiogenesis Inhibitors and Hypertension: An Emerging Issue, Journal of Clinical Oncology, vol.24, issue.9, pp.1329-1331, 2006.
DOI : 10.1200/JCO.2005.04.5740

H. M. Verheul and H. M. Pinedo, Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nature Reviews Cancer, vol.290, issue.6, pp.475-485, 2009.
DOI : 10.1038/nrc2152

G. Vrijens, P. Vincze, J. Kristanto, M. Urquhart, and . Burnier, Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories, BMJ, vol.336, issue.7653, pp.1114-1117, 2008.
DOI : 10.1136/bmj.39553.670231.25

G. Corrao, A. Zambon, and A. Parodi, Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy, Journal of Hypertension, vol.26, issue.4, pp.819-824, 2008.
DOI : 10.1097/HJH.0b013e3282f4edd7

W. A. De-souza, M. Sabha, F. De-faveri-favero, G. Bergsten-mendes, J. C. Yugar-toledo et al., Intensive Monitoring of Adherence to Treatment Helps to Identify ???True??? Resistant Hypertension, The Journal of Clinical Hypertension, vol.288, issue.1 suppl 1, pp.183-191, 2009.
DOI : 10.1111/j.1751-7176.2009.00102.x

J. Park and V. Campese, Clinical Characteristics of Resistant Hypertension: The Importance of Compliance and the Role of Diagnostic Evaluation in Delineating Pathogenesis, The Journal of Clinical Hypertension, vol.48, issue.2, pp.7-12, 2007.
DOI : 10.1111/j.1524-6175.2007.6106.x

C. L. Trewet and M. E. Ernst, Resistant Hypertension: Identifying Causes and Optimizing Treatment Regimens, Southern Medical Journal, vol.101, issue.2, pp.166-173, 2008.
DOI : 10.1097/SMJ.0b013e31816171cb

L. S. Phillips, W. T. Branch, and C. B. Cook, Clinical Inertia, Annals of Internal Medicine, vol.135, issue.9, pp.825-834, 2001.
DOI : 10.7326/0003-4819-135-9-200111060-00012

E. M. Furmaga, F. E. Cunningham, and W. C. Cushman, National Utilization of Antihypertensive Medications From 2000 to 2006 in the Veterans Health Administration: Focus on Thiazide Diuretics, The Journal of Clinical Hypertension, vol.145, issue.10, pp.770-778, 2008.
DOI : 10.1111/j.1751-7176.2008.00019.x

M. Egan, Y. Zhao, and R. N. Axon, US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008, JAMA, vol.303, issue.20, pp.2043-2050, 1988.
DOI : 10.1001/jama.2010.650

G. Mancia, G. De-backer, and A. Dominiczak, 2007 Guidelines for the Management of Arterial Hypertension, Journal of Hypertension, vol.25, issue.6, pp.1105-1187, 2005.
DOI : 10.1097/HJH.0b013e3281fc975a

J. Garg, W. Elliott, A. Folker, M. Izhar, H. Black et al., Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts, American Journal of Hypertension, vol.18, issue.5, pp.619-626, 2005.
DOI : 10.1016/j.amjhyper.2004.11.021

R. Asmar, P. Gosse, S. Queré, and A. Achouba, Efficacy of morning and evening dosing of amlodipine/valsartan combination hypertensive patients uncontrolled by 5 mg of amlodipine Blood Press Monit, pp.80-86, 2011.

B. Materson, D. Reda, W. Cushman, and W. Henderson, Results of combination antihypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents, J Hum Hypertens, vol.9, pp.791-796, 1995.

S. Taler, S. Textor, and J. Augustine, Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care, Hypertension, vol.39, issue.5, pp.982-988, 2002.
DOI : 10.1161/01.HYP.0000016176.16042.2F

M. Ernst, B. Carter, C. Goerdt, J. Steffensmeier, B. Phillips et al., Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure, Hypertension, vol.47, issue.3, pp.352-358, 2006.
DOI : 10.1161/01.HYP.0000203309.07140.d3

R. C. Hermida, D. E. Ayala, J. R. Fernandez, and C. Calvo, Chronotherapy Improves Blood Pressure Control and Reverts the Nondipper Pattern in Patients With Resistant Hypertension, Hypertension, vol.51, issue.1, pp.69-76, 2008.
DOI : 10.1161/HYPERTENSIONAHA.107.096933

B. Staessen, J. Thijs, L. Fagard, R. , O. Brien et al., Predicting Cardiovascular Risk Using Conventional vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension, Systolic Hypertension in Europe Trial Investigators, pp.539-546, 1999.
DOI : 10.1001/jama.282.6.539

M. Kikuya, T. Ohkubo, K. Asayama, H. Metoki, T. Obara et al., Ambulatory Blood Pressure and 10-Year Risk of Cardiovascular and Noncardiovascular Mortality: The Ohasama Study, Hypertension, vol.45, issue.2, pp.240-245, 2005.
DOI : 10.1161/01.HYP.0000152079.04553.2c

J. Ouzan, C. Perault, A. M. Lincoff, E. Carr´e, and M. Mertes, The role of spironolactone in the treatment of patients with refractory hypertension, American Journal of Hypertension, vol.15, issue.4, pp.333-339, 2002.
DOI : 10.1016/S0895-7061(01)02342-1

B. Nishizaka, M. Zaman, M. Calhoun, and D. , Efficacy of low-dose spironolactone in subjects with resistant hypertension, American Journal of Hypertension, vol.16, issue.11, pp.925-930, 2003.
DOI : 10.1016/S0895-7061(03)01032-X

F. De-souza, E. Muxfeldt, R. Fiszman, G. S. Salles-71, K. P. Hood et al., Efficacy of spironolactone therapy in patients with true resistant hypertension The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low renin hypertension and elevated aldosterone 72 Anti-vascular endothelial growth factor (VEGF) therapy: a new cause of secondary hypertension. Rev Prat, Urgences néphrologiques et transplantation rénale, Inserm U702, hôpital Tenon, pp.147-152644, 2010.

S. Wu, J. J. Chen, A. Kudelka, J. Lu, and X. Zhu, Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis, The Lancet Oncology, vol.9, issue.2, pp.117-123, 2008.
DOI : 10.1016/S1470-2045(08)70003-2

K. Vishesh, M. Kapur, and . Mph, Obstructive Sleep Apnea: Diagnosis, Epidemiology, and Economics. Respiratory Care, septembre 2010, p.9

F. Nieto, T. Young, B. Lind, E. Shahar, J. Samet et al., Association of Sleep-Disordered Breathing, Sleep Apnea, and Hypertension in a Large Community-Based Study, JAMA, vol.283, issue.14, pp.1829-1836, 2000.
DOI : 10.1001/jama.283.14.1829

P. Peppard, T. Young, M. Palta, and J. Skatrud, Prospective Study of the Association between Sleep-Disordered Breathing and Hypertension, New England Journal of Medicine, vol.342, issue.19, pp.1378-1384, 2000.
DOI : 10.1056/NEJM200005113421901

A. Logan, S. Perlikowski, A. Mente, A. Tisler, R. Tkacova et al., High prevalence of unrecognized sleep apnoea in drug-resistant hypertension, Journal of Hypertension, vol.19, issue.12, pp.2271-2277, 2001.
DOI : 10.1097/00004872-200112000-00022

L. Grote, J. Hedner, and J. Peter, Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension, Journal of Hypertension, vol.18, issue.6, pp.679-685, 2000.
DOI : 10.1097/00004872-200018060-00004

P. Lavie and V. Hoffstein, Sleep Apnea Syndrome: A Possible Contributing Factor to Resistant Hypertension, Sleep, vol.24, issue.6, pp.721-725, 2001.
DOI : 10.1093/sleep/24.6.721

V. Somers, M. Dyken, M. Clary, and F. Abboud, Sympathetic neural mechanisms in obstructive sleep apnea., Journal of Clinical Investigation, vol.96, issue.4, pp.1897-1904, 1995.
DOI : 10.1172/JCI118235

G. Grassi, A. Facchini, F. Trevano, R. Dell-'oro, F. Arenare et al., Obstructive Sleep Apnea-Dependent and -Independent Adrenergic Activation in Obesity, Hypertension, vol.46, issue.2, pp.321-325, 2005.
DOI : 10.1161/01.HYP.0000174243.39897.6c

L. Lavie, A. Hefetz, R. Luboshitzky, and P. Lavie, Plasma Levels of Nitric Oxide and L-Arginine in Sleep Apnea Patients: Effects of nCPAP Treatment, Journal of Molecular Neuroscience, vol.21, issue.1, pp.57-63, 2003.
DOI : 10.1385/JMN:21:1:57

G. Robinson, J. Stradling, and R. Davies, Sleep {middle dot} 6: Obstructive sleep apnoea/hypopnoea syndrome and hypertension, Thorax, vol.59, issue.12, pp.1089-1094, 2004.
DOI : 10.1136/thx.2003.015875

J. W. Conn, Presidential address. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism, Journal of Laboratory and Clinical Medicine Annals of Internal Medicine, vol.45, issue.66 6, pp.3-17, 1955.

R. Fagugli and C. Taglioni, Changes in the Perceived Epidemiology of Primary Hyperaldosteronism, International Journal of Hypertension, vol.341, issue.7258, p.162804, 2011.
DOI : 10.2215/CJN.04750908

N. M. Kaplan, Is There an Unrecognized Epidemic of Primary Aldosteronism? (Con), Hypertension, vol.50, issue.3, pp.454-458, 2007.
DOI : 10.1161/HYPERTENSIONAHA.106.086124

C. Fardella, L. Mosso, and C. Carvajal, Primary aldosteronism, Rev Med Chil, 2008.

C. Fardella, L. Mosso, C. Gómez-sánchez, P. Cortés, J. Soto et al., Primary Hyperaldosteronism in Essential Hypertensives: Prevalence, Biochemical Profile, and Molecular Biology, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.5, pp.1863-1867, 2000.
DOI : 10.1210/jc.85.5.1863

M. Stowasser and R. D. Gordon, Primary aldosteronism???careful investigation is essential and rewarding, Molecular and Cellular Endocrinology, vol.217, issue.1-2, pp.33-39, 2004.
DOI : 10.1016/j.mce.2003.10.006

P. Mulatero, R. G. Dluhy, G. Giacchetti, M. Boscaro, F. Veglio et al., Diagnosis of primary aldosteronism: from screening to subtype differentiation, Trends in Endocrinology & Metabolism, vol.16, issue.3, pp.114-119, 2005.
DOI : 10.1016/j.tem.2005.02.007

D. Calhoun, M. Nishizaka, M. Zaman, R. Thakkar, and P. Weissmann, Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension, Hypertension, vol.40, issue.6, pp.892-896, 2002.
DOI : 10.1161/01.HYP.0000040261.30455.B6

J. Gallay, S. Ahmad, L. Xu, B. Toivola, and R. C. Davidson, Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio, American Journal of Kidney Diseases, vol.37, issue.4, pp.699-705, 2001.
DOI : 10.1016/S0272-6386(01)80117-7

S. Douma, K. Petidis, and M. Doumas, Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study, The Lancet, vol.371, issue.9628, pp.1921-1926, 2008.
DOI : 10.1016/S0140-6736(08)60834-X

C. Faselis, M. Doumas, and V. Papademetriou, Common Secondary Causes of Resistant Hypertension and Rational for Treatment, International Journal of Hypertension, vol.281, issue.6248, 236239.
DOI : 10.1016/S0140-6736(09)60566-3

F. Mantero, M. Mattarello, and N. Albiger, Detecting and Treating Primary Aldosteronism, Experimental and Clinical Endocrinology & Diabetes, vol.115, issue.3, pp.171-175, 2007.
DOI : 10.1055/s-2007-970409

B. Stowasser, M. Gordon, R. Gunasekera, T. Cowley, D. Ward et al., High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients J Hypertens, 2003.

. Rossi, Primary aldosteronism : Part I, J Nephrol, vol.21, pp.447-454, 2008.

G. Rossi, T. Seccia, and A. Pessina, Primary aldosteronism: part II: subtype differentiation and treatment, J Nephrol, vol.21, issue.4, pp.455-62, 2008.

M. Kempers, J. Lenders, L. Van-outheusden, G. Van-der-wilt, S. Kool et al., Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism, Annals of Internal Medicine, vol.151, issue.5, pp.329-366, 2009.
DOI : 10.7326/0003-4819-151-5-200909010-00007

S. Engeli, J. Böhnke, K. Gorzelniak, J. Janke, P. Schling et al., Weight Loss and the Renin-Angiotensin-Aldosterone System, Hypertension, vol.45, issue.3, pp.356-362, 2005.
DOI : 10.1161/01.HYP.0000154361.47683.d3

M. Ehrhart-bornstein, V. Lamounier-zepter, A. Schraven, J. Langenbach, H. Willenberg et al., Human adipocytes secrete mineralocorticoid-releasing factors, Proceedings of the National Academy of Sciences, vol.100, issue.24, pp.14211-14216, 2003.
DOI : 10.1073/pnas.2336140100

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC283571

C. Gonzaga, K. K. Gaddam, and M. I. Ahmed, Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension, Journal of Clinical Sleep Medicine, vol.6, issue.4, pp.363-368, 2010.

D. Calhoun, M. Nishizaka, M. Zaman, and S. Harding, Aldosterone Excretion Among Subjects With Resistant Hypertension and Symptoms of Sleep Apnea, Chest, vol.125, issue.1, pp.112-117, 2004.
DOI : 10.1378/chest.125.1.112

R. Safian and S. Textor, Renal-Artery Stenosis, New England Journal of Medicine, vol.344, issue.6, pp.431-442, 2001.
DOI : 10.1056/NEJM200102083440607

K. Hansen, M. Edwards, T. Craven, G. Cherr, S. Jackson et al., Prevalence of renovascular disease in the elderly: A population-based study, Journal of Vascular Surgery, vol.36, issue.3, pp.443-51, 2002.
DOI : 10.1067/mva.2002.127351

R. Aqel, G. Zoghbi, S. Baldwin, W. Auda, D. Calhoun et al., Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization., Journal of Hypertension, vol.21, issue.6, pp.1157-1162, 2003.
DOI : 10.1097/00004872-200306000-00016

J. Crowley, R. Santos, R. Peter, J. Puma, S. Schwab et al., Progression of renal artery stenosis in patients undergoing cardiac catheterization, American Heart Journal, vol.136, issue.5, pp.913-918, 1998.
DOI : 10.1016/S0002-8703(98)70138-3

T. Leiner, M. De-haan, P. Nelemans, J. Van-engelshoven, and G. Vasbinder, Contemporary imaging techniques for the diagnosis of renal artery stenosis, European Radiology, vol.9, issue.Suppl 5, pp.2219-2229, 2005.
DOI : 10.1007/s00330-005-2826-6

B. Van-jaarsveld, P. Krijnen, H. Pieterman, F. Derkx, J. Deinum et al., The Effect of Balloon Angioplasty on Hypertension in Atherosclerotic Renal-Artery Stenosis, New England Journal of Medicine, vol.342, issue.14, pp.1007-1014, 2000.
DOI : 10.1056/NEJM200004063421403

N. Ives, K. Wheatley, R. Stowe, P. Krijnen, P. Plouin et al., Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials, Nephrology Dialysis Transplantation, vol.18, issue.2, pp.298-304, 2003.
DOI : 10.1093/ndt/18.2.298

P. Plouin and L. Bax, Diagnosis and treatment of renal artery stenosis, Nature Reviews Nephrology, vol.21, issue.3, pp.151-160, 2010.
DOI : 10.1038/nrneph.2009.230

J. Coresh, G. Wei, G. Mcquillan, F. Brancati, A. Levey et al., Prevalence of High Blood Pressure and Elevated Serum Creatinine Level in the United States, Archives of Internal Medicine, vol.161, issue.9, pp.1207-1216, 1988.
DOI : 10.1001/archinte.161.9.1207

M. Saelen, L. Prøsch, H. Gudmundsdottir, D. Dyrbekk, H. Hunderi et al., Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate???to???severe reductions in renal function, Blood Pressure, vol.12, issue.21, pp.170-176, 2005.
DOI : 10.1016/S0140-6736(96)11445-8

J. Adler, G. Meyer-rochow, H. Chen, D. Benn, B. Robinson et al., Sidhu SB Pheochromocytoma: current approaches and future directions Oncologist, pp.779-93, 2008.

K. Björklund, L. Lind, B. Zethelius, L. Berglund, and H. Lithell, Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men, Journal of Hypertension, vol.22, issue.9, pp.1691-1697, 2004.
DOI : 10.1097/00004872-200409000-00012

M. Kikuya, A. Hozawa, T. Ohokubo, I. Tsuji, M. Michimata et al., Prognostic Significance of Blood Pressure and Heart Rate Variabilities : The Ohasama Study, Hypertension, vol.36, issue.5, pp.901-906, 2000.
DOI : 10.1161/01.HYP.36.5.901

A. Sinclair, C. Isles, I. Brown, H. Cameron, G. Murray et al., Secondary Hypertension in a Blood Pressure Clinic, Archives of Internal Medicine, vol.147, issue.7, pp.1289-1293, 1987.
DOI : 10.1001/archinte.1987.00370070103015

L. Amar, A. Servais, A. Gimenez-roqueplo, F. Zinzindohoue, G. Chatellier et al., Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.4, pp.2110-2116, 2005.
DOI : 10.1210/jc.2004-1398

M. Sutton, S. Sheps, and J. Lie, Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series, Mayo Clinic Proc, vol.56, pp.354-360, 1981.

A. Sawka, R. Jaeschke, and R. Singh, A Comparison of Biochemical Tests for Pheochromocytoma: Measurement of Fractionated Plasma Metanephrines Compared with the Combination of 24-Hour Urinary Metanephrines and Catecholamines, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.2, pp.553-558, 2003.
DOI : 10.1210/jc.2002-021251

G. Smythe, G. Edwards, and P. Graham, Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine, Clin Chem, vol.38, pp.486-492, 1992.

J. Harding, M. Yeh, and B. Robinson, Potential pitfalls in the diagnosis of phaeochromocytoma, Med J Aust, vol.182, pp.637-640, 2005.

J. Lenders, K. Pacak, and M. Walther, Biochemical Diagnosis of Pheochromocytoma, JAMA, vol.287, issue.11, pp.1427-1434, 2002.
DOI : 10.1001/jama.287.11.1427

E. Bravo, Pheochromocytoma: New concepts and future trends, Kidney International, vol.40, issue.3, pp.544-556, 1991.
DOI : 10.1038/ki.1991.244

S. Maurea, A. Cuocolo, and J. Reynolds, Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: Comparison with CT andMRI, J Nucl Med, vol.34, pp.173-179, 1993.

E. Bravo and R. Tagle, Pheochromocytoma: State-of-the-Art and Future Prospects, Endocrine Reviews, vol.24, issue.4, pp.539-553, 2003.
DOI : 10.1210/er.2002-0013

I. Ilias and K. Pacak, Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome Endocr Regul, pp.89-93, 2009.

B. Treadwell, E. Sever, and O. Savage, SIDE-EFFECTS OF LONG-TERM TREATMENT WITH CORTICOSTEROIDS AND CORTICOTROPHIN, The Lancet, vol.283, issue.7343, pp.1121-1124, 1964.
DOI : 10.1016/S0140-6736(64)91804-5

P. Ferrari, Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease, Best Practice & Research Clinical Endocrinology & Metabolism, vol.17, issue.4, pp.575-589, 2003.
DOI : 10.1016/S1521-690X(03)00053-8

L. Nieman, B. Biller, and J. Findling, The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.5, pp.1526-1566, 2008.
DOI : 10.1210/jc.2008-0125

C. Speiker, M. Barenbrock, and K. Rahn, Circadian Blood Pressure Variations in Endocrine Disorders, Blood Pressure, vol.8, issue.1, pp.35-44, 1993.
DOI : 10.1161/01.HYP.12.1.11

S. Mcfarlane, M. Banerji, and J. Sowers, Insulin Resistance and Cardiovascular Disease, Journal of Clinical Endocrinology & Metabolism, vol.86, issue.2, pp.713-718, 2001.
DOI : 10.1210/jc.86.2.713

A. Sacerdote, K. Weiss, T. Tran, R. Noor, B. Mcfarlane et al., Hypertension in patients with cushing???s disease: Pathophysiology, diagnosis, and management, Current Hypertension Reports, vol.42, issue.3, pp.212-218, 2005.
DOI : 10.1007/s11906-005-0013-4

G. Arnaldi, T. Mancini, B. Polenta, and M. Boscaro, Cardiovascular Risk In Cushing's Syndrome, Pituitary, vol.17, issue.4, pp.253-256, 2004.
DOI : 10.1007/s11102-005-1172-7

M. Muiesan, M. Lupia, M. Salvetti, C. Grigoletto, N. Sonino et al., Left ventricular structural and functional characteristics in Cushing???s syndrome, Journal of the American College of Cardiology, vol.41, issue.12, pp.2275-2279, 2003.
DOI : 10.1016/S0735-1097(03)00493-5

A. Faggiano, R. Pivonello, S. Spiezia, D. Martino, M. Filippella et al., Cardiovascular Risk Factors and Common Carotid Artery Caliber and Stiffness in Patients with Cushing???s Disease during Active Disease and 1 Year after Disease Remission, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.6, pp.2527-2533, 2003.
DOI : 10.1210/jc.2002-021558

S. Zacharieva, M. Orbetzova, and E. Natchev, Losartan in Cushing's syndrome, Methods and Findings in Experimental and Clinical Pharmacology, vol.20, issue.2, pp.163-168, 1998.
DOI : 10.1358/mf.1998.20.2.472459

L. Bakris, L. H. Lindholm, and H. R. Black, Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial, Hypertension, vol.56, issue.5, pp.824-830, 2010.
DOI : 10.1161/HYPERTENSIONAHA.110.156976

J. Oliver, J. W. Dear, and D. J. Webb, Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension, Hypertension, vol.56, issue.1, pp.62-67, 2010.
DOI : 10.1161/HYPERTENSIONAHA.109.147686

J. Saseen, B. Carter, T. Brown, W. Elliott, and H. Black, Comparison of Nifedipine Alone and With Diltiazem or Verapamil in Hypertension, Hypertension, vol.28, issue.1, pp.109-114, 1996.
DOI : 10.1161/01.HYP.28.1.109

M. Doumas, D. Guo, and V. Papademetriou, Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions, Expert Opinion on Therapeutic Targets, vol.277, issue.4, pp.413-425, 2009.
DOI : 10.1161/01.RES.41.6.750

M. Ng, D. Sica, and W. Frishman, Rheos, Cardiology in Review, vol.19, issue.2, pp.52-59, 2011.
DOI : 10.1097/CRD.0b013e3181f87921

N. Joshi, J. Taylor, and J. Bisognano, Implantable device therapy for the treatment of resistant hypertension J Cardiovasc Transl Res, pp.150-153, 2009.

J. Taylor and J. Bisognano, Baroreflex Stimulation in Antihypertensive Treatment, Current Hypertension Reports, vol.6, issue.5
DOI : 10.1007/s11906-010-0106-6

M. Rothstein, Chronic treatment of resistant hypertension with an implantable device: interim 2 year results of two studies of the Rheos hypertension system. The heart, 2009.

J. M. Scheffers, A. A. Kroon, and J. Schmidli, Novel Baroreflex Activation Therapy in Resistant Hypertension, Journal of the American College of Cardiology, vol.56, issue.15, pp.1254-1258, 2010.
DOI : 10.1016/j.jacc.2010.03.089

M. Doumas, C. Faselis, and V. Papademetriou, Renal Sympathetic Denervation and Systemic Hypertension, The American Journal of Cardiology, vol.105, issue.4, pp.570-576, 2010.
DOI : 10.1016/j.amjcard.2009.10.027

V. Papademetriou, M. Doumas, and K. Tsioufis, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, International Journal of Hypertension, vol.1, issue.5, 2011.
DOI : 10.1016/S0140-6736(10)62039-9

H. Krum, M. Schlaich, and R. Whitbourn, Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study, The Lancet, vol.373, issue.9671, pp.1275-1281, 2009.
DOI : 10.1016/S0140-6736(09)60566-3

H. Symplicity, . Investigators, M. Esler, H. Krum, P. Sobotka et al., Böhm M Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet, pp.1903-1912, 2010.

P. Sarafidis, Epidemiology of Resistant Hypertension, The Journal of Clinical Hypertension, vol.371, issue.9628, 2011.
DOI : 10.1111/j.1751-7176.2011.00445.x

L. Débit-cardiaque and D. Le-produit, Volume d'Ejection Systolique (VES) x Fréquence Cardiaque (FC)

L. Systèmes-de-régulation-de-la and T. , -le Système Nerveux Sympathique : via la sécrétion de catécholamines (retrouvées dans le Phéochromocytome) permet l'augmentation du DC et des RAS

-. and S. Rénine, Angiotensine-Aldostérone (SRAA) : effets vasoconstricteurs de l'angiotensine II et de la rétention hydro-sodée induite par l'aldostérone

-. and M. Sodé, la volémie et l'homéostasie du sel est assurée par la fonction régulatrice du rein : l'excrétion rénale est fonction du débit de filtration glomérulaire, de l'aldostérone